

**Application** Atty. Docket No. 0501-UTL-0

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:

10/559,595

**Inventors:** 

John ONG, et al

Filed:

November 30, 2005

Title: NOVEL METHODS AND COMPOSITIONS FOR ENHANCED TRANSMUCOSAL DELIVERY OF

PEPTIDES AND PROTEINS

Confirmation No.: Not Yet Assigned

TC/A.U.: Not Yet Assigned

Examiner: Not Yet Assigned

#### TRANSMITTAL LETTER

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The following documents are enclosed herewith for your review and consideration:

- Information Disclosure Statement under 37 CFR 1.56 (2 pages)
  - Including 25 copies of references
  - PTO SB08 Form (4 pages)
- Return Post Card

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.

Dated: March 9, 2006

Timothy E. Torchia

Registration No. 36,700

AMYLIN PHARMACEUTICALS. INC.

9360 Towne Centre Drive San Diego, CA 92121

Telephone: 858.552.2200

Facsimile: 858.552.1936

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8a OR FACSIMILE TRANSMISSION UNDER 37 C.F.R. 1.8

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the USPTO at facsimile number (571) 273-8300, or deposited with the United States Postal Service on the date shown below with sufficient First Class postage in an envelope addressed to the Commissioner for Patents, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below

Date of Deposit

Name of Person Mailing Paper

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.:

10/559,595

**Inventors:** 

ONG, John, et al

Filed:

November 30, 2005

Title: NOVEL METHODS AND COMPOSITIONS FOR

ENHANCED TRANSMUCOSAL DELIVERY OF

PEPTIDES AND PROTEINS

Confirmation No.: Not Yet

Assigned

TC/A.U.: Not Yet Assigned

Examiner: Not Yet Assigned

#### INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

In compliance with 37 C.F.R. §1.56, the patent documents listed on the attached Form PTO/SB/08A are being submitted herewith for consideration by the Examiner. In accordance with 37 C.F.R. 1.98, a copy of each of the listed items, other than U.S. Patents and U.S. Patent Application Publications, is included herewith.

The references are being cited only in the interests of candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. 1.97(b) in that Applicants believe that it is being filed before the mailing date of the first Office Action

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8a OR FACSIMILE TRANSMISSION UNDER 37 C.F.R. 1.8

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the USPTO at facsimile number (571) 273-8300, or deposited with the United States Postal Service on the date shown below with sufficient First Class postage in an envelope addressed to the Commissioner for Patents, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Date of Deposit

Signature of Person Mailing Paper

Name of Person Mailing Paper

on the merits. Accordingly, neither a statement nor a fee under 37 C.F.R. 1.97(c) is required. If Applicants are mistaken, and the mailing date of the first Office Action on the merits precedes the filing of this Supplemental Information Disclosure Statement, Applicants authorize that the fee due under 37 C.F.R. 1.17(p) be charged to Deposit Account No 010535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully Submitted

AMYLIN PHARMACEUTICALS, INC.

Dated: 09 Mar 06

Registration No. 36,700

AMYLIN PHARMACEUTICALS, INC.

9373 Towne Centre Drive San Diego, CA 92121

Telephone: (858) 552-2200 Facsimile: (858) 552-1936

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

/ U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE he Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

TO THE OWNER.

Sheet

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/559,595		
Filing Date	November 30, 2005		
First Named Inventor	ONG, John, et al		
Art Unit	1654		
Examiner Name	Not Yet Assigned		
Attorney Docket Number	0501-UTL-0		

			U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	<sup>US-</sup> 4,476,116	10-09-1984	SHABBIR, T. Anik	
	2	<sup>US-</sup> 4,847,240	07-11-1989	RYSER, et al	
	3	<sup>US-</sup> 5,116,817	05-26-1992	SHABBIR, T. Anik	
	4	<sup>US-</sup> 5,124,314	06-23-1992	COOPER, Garth J. S.	
	5	<sup>US-</sup> 5,367,052	11-22-1994	COOPER, Garth, et al	
	6	<sup>US-</sup> 5,512,549	04-30-1996	CHEN, Victor J.	
	7	<sup>US-</sup> 5,554,388	09-10-1996	ILLUM, Lisbeth	
	8	<sup>US-</sup> 5,574,008	11-12-1996	JOHNSON, William, et al	
	9	<sup>US-</sup> 5,788,959	08-04-1998	SINGH, Manish	
	10	<sup>US-</sup> 5,580,953	12-03-1996	ALBRECHT, Elisabeth, et al	
-	11	<sup>US-</sup> 5,686,411	11-11-1997	GAETA, Laura, et al	
	12	<sup>US-</sup> 5,705,483	01-06-1998	GALLOWAY, John, et al	
	13	<sup>US-</sup> 5,788,959	08-04-1998	SINGH, Manish	
	14	<sup>US-</sup> 5,804,212	09-08-1998	ILLUM, Lisbeth	
	15	<sup>US-</sup> 5,977,070	11-02-1999	PIAZZA, Christin, et al	
	16	<sup>US-</sup> 5,981,488	11-09-1999	HOFFMANN, James	
	17	<sup>US-</sup> 6,294,153	09-25-2001	MODI, Pankaj	
	18	<sup>US-</sup> 6,391,318	05-21-2002	ILLUM, Lisbeth, et al	
	19	<sup>US-</sup> 6,440,392	08-27-2002	STERN, William	

	FOREIGN PATENT DOCUMENTS							
	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages			
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> ( <i>if known</i> )	MM-DD-YYYY		Or Relevant Figures Appear	T⁵		
	20	JP 1998095738 A	04-14-1998	MORIMOTO, Y., et al		V		
	21	JP 2000281589 A	10-10-2000	MORIMOTO, Y., et al		V		
	22	WO 99/07404 A1	02-18-1999	BEELEY, Nigel, et al				
	23	WO 99/25727 A2	05-27-1999	BEELEY, Nigel, et al				
	24	WO 99/25728 A1	05-27-1999	BEELEY, Nigel, et al				
	25	WO 00/41546 A2	07-20-2000	YOUNG, Andrew, et al				

Examiner Signature	*****	•	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/559,595 Filing Date November 30, 2005 INFORMATION DISCLOSURE First Named Inventor ONG, John, et al STATEMENT BY APPLICANT Art Unit 1654 (Use as many sheets as necessary) Examiner Name Not Yet Assigned

Sheet		2 of	4	Attorney Docket Number 0	501-UTL-0
			II S DATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Docume	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	26	<sup>US-</sup> 6,528,486	03-04-2003	LARSEN, Bjame, et al	
	27	<sup>US-</sup> 6,610,824	08-26-2003	GAETA, Laura, et al	
	28	<sup>US-</sup> 2002/0137666 A1	09-26-2002	ROBERT, Nigel, et al	
	29	<sup>US-</sup> 2002/0141985 A1	10-03-2002	PITTNER, Richard, et al	
	30	<sup>US-</sup> 2003/0087820 A1	05-08-2003	YOUNG, Andrew, et al	
	31	<sup>US-</sup> 2003/0087821 A1	05-08-2003	ROBERT, Nigel, et al	
	32	<sup>US-</sup> 2003/0220243 A1	11-27-2003	GLAESNER, Wolfgang, et al	
	33	<sup>US-</sup> 2004/0053819 A1	03-18-2004	DODD, Steven, et al	
		US-			
	t	US-		<u> </u>	

FOREIGN PATENT DOCUMENTS						
Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
	Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T°	
34	WO 00/66629 A1	11-09-2000	YOUNG, A., et al			
 35	WO 01/04156 A1	01-18-2001	LARSEN, B., et al			
36	WO 01/98331 A2	12-27-2001	GLAESNER, W., et al			
 37	WO 02/47712 A2	06-20-2002	PITTNER, R., et al			
38	WO 02/48192 A2	06-20-2002	MILLICAN, R., et al			
 39	WO 03/026591 A2	04-03-2003	COWLEY, M., et al			

	 _			
Examiner			Date	
Signature			Considered	
			1	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Pagerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitut	e for form 1449/PTO			Complete if Known		
				Application Number	10/559,595	
INFO	DRMATION	DIS	CLOSURE	Filing Date	November 30, 2005	
STA	STATEMENT BY APPLICANT		First Named Inventor	ONG, John, et al		
	(Ilse as many she	ate ae ni	eraceany)	Art Unit	1654	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	3	of	4	Attorney Docket Number	0501-UTL-0	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	40	CALLENS, C., et al, "Evaluation of Starch-Maltodextrin-Carbopol 974 Mixtures for the Nasal Delivery of Insulin in Rabbits", J. Control Release, 2000, pp 215-220, Vol. 66(2-3)	
	41	DAVIS, S. and ILLUM, L., "Absorption Enhancers for Nasal Drug Delivery", Clin Pharmacokinet., 2003, pp 1107-1128, Vol. 42(13)	
	42	DYER, A.M., et al, "Nasal Delivery of Insulin Using Novel Chitosan Based Formulations: A Comparative Study", Pharm Res., 2002, pp 998-1008, Vol., 19(7)	
	43	FERNANDEZ-URRUSUNO, R., et al, "Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles", Pharm Res., 1999 Oct., pp1576-1581, Vol. 16(10)	
	44	ILLUM, L., et al, "Chitosan as a Novel Nasal Delivery System for Peptide Drugs", Pharm Res., 1994 Aug, pp 1186-1189, Vol. 11(8)	
	45	KYTE, J., et al, "A Simple Method for Displaying the Hydropathic Character of a Protein", J Mol Biol., 1982 May, pp 105-132, Vol. 157(1)	
	46	McEWAN, G.T., et al, "Polycation-Induced Enhancement of Epithelial Paracellular Permeability", Biochem Biophys Acta., 1993 May 14, pp 51-60, Vol. 1148(1)	
	47	MIYAMOTO, M., et al, "Improved Nasal Absorption of Drugs Using Poly-L-Arginine: Effects of Concentration", Eur J Pharm Biopharm, 2001 July, pp 21-30, Vol. 52(1)	
	48	MIYAMOTO, M., et al, "Effect of Poly-L-Arginine on the Nasal Absorption", Int J Pharm., 2001 Sep 11, pp 127-138, Vol. 226(1-2)	
	49	NATSUME, H., et al, "Screening of Cationic Compound as an Absorption Enhancer", Int J Pharm., 1999 Aug 5, pp 1-12, Vol. 185(1)	

Examiner	· · · · · · · · · · · · · · · · · ·	Date	
Signature		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Parallection of information unless it contains a valid OMB control number.

	te for form 1449/PTO		a or 1999, no persons ar	Complete if Known		
				Application Number	10/559,595	
			CLOSURE	Filing Date	November 30, 2005	
STA	STATEMENT BY APPLICANT		First Named Inventor	ONG, John, et al		
	STATEMENT BY APPLICAN (Use as many sheets as necessary)			Art Unit	1654	
	(Use as many sneets as necessary)		Examiner Name	Not Yet Assigned		
Sheet	4	of	4	Attorney Docket Number	0501-UTL-0	

Evamina:	Cit-	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	50	OHTAKE, K., et al, "Analysis of Transient and Reversible Effects of Poly-L-Arginine on the In Vivo Nasal", J Control Release, 2002 Aug 21, pp 263-275, Vol. 82(2-3)	
	51	OHTAKE, K., et al, "Poly-L-Arginine Enhances Paracellular Permeability Via Serine/Threonine Phosphorylation" Pharm Res., 2003 Nov., pp1838-1845, Vol. 20(11)	
	52	UCHIDA, D.A., et al, "Cationic Proteins Increase the Permeability of Cultured Rabbit Tracheal Epithelial" Exp Lung Res., 1996 Jan - 1996 Feb, pp 85-99, Vol. 22(1)	

Examiner	Date	_
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup> Applicant to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.